C5 and hemolytic-uremic syndrome: Given our observations both in vivo and in vitro that Stx2 leads to a reduction in GEnC CFH binding and subsequent endothelial complement activation, we attempted to rescue the HUS phenotype using the C5 complement inhibitor BB5.1.